Skip to content
Low DoseGLP-1Providers

Evidence review

New GLP-1 Vial? Check the Concentration First

The same syringe marking can contain a different amount of medicine after a refill. Learn what to verify when a compounded GLP-1 label changes.

Written Lena Ortiz

On this page

Do not carry a syringe marking from an old compounded GLP-1 vial to a new one without checking the current instructions. The prescribed amount of medicine and the concentration in the vial are different pieces of information. FDA has documented dosing mistakes involving these differences, sometimes requiring hospitalization 1.

Featured partner

CoreAge Rx

$149–$199/mo microdose ($99–$149 standard)

Two named microdosing programs with their own monthly prices, sold beside standard plans that cost less.

Check availability
Category
Telehealth · GLP-1 microdose
Pricing
Flat monthly price
Support
Clinician review included
Labs
No labs required

Advertising disclosure · an affiliate partner. We may earn a commission at no extra cost to you.

Partner

ShedRx (Shed)

A named microdose of either molecule priced below its standard injection, beside lozenges and drops.

$149–$199/mo microdose (2-month minimum)

Check ShedRx (Shed) availability

This guide explains what to compare on a refill and what to ask the pharmacy. It does not provide a conversion chart or tell you which dose to take. If the label, syringe and prescriber's message do not agree, resolve the discrepancy before injecting.

What matters for a low-dose plan

  • Syringe markings measure volume, not a universal GLP-1 dose.
  • Compare the current label and directions at every refill.
  • Resolve mismatched concentration or syringe instructions before injecting.
Sources and limitations are explained below.

Dose, concentration and volume answer different questions

A dose describes how much active medicine the prescriber intends you to receive. Concentration describes how much medicine is present in a given volume of liquid. Syringe markings help measure volume; they do not independently identify the medicine or its dose.

That is why a familiar-looking syringe is not enough. The same marking can represent a different amount of drug if the concentration changes. FDA specifically warns about confusion between milligrams, milliliters and "units" in compounded semaglutide instructions 1.

This distinction remains important for a very small prescribed amount. Calling a program a microdose does not standardize its concentration, vial size, syringe or instructions. Two patients using the same program name may not have identical prescriptions.

Why the total amount on the vial can be misleading

A label may show the total medicine in the container as well as a concentration and the total liquid volume. Those numbers are related, but they are not interchangeable. A larger total amount does not automatically mean the same concentration, and a similar-looking vial does not prove the refill is identical.

Instead of selecting one number that looks familiar, ask the pharmacist to identify the active ingredient, concentration, prescribed dose and corresponding measuring instructions on the actual label. Confirm which syringe those instructions assume.

Do not use a photograph from a forum as a template. It may show a different concentration, an older prescription, a different pharmacy or a different drug. The appearance of the vial is not sufficient evidence that the instructions apply to you.

A refill comparison that does not require mental arithmetic

Put the old and new labels beside each other and check the patient name, medicine name, pharmacy, concentration, directions and dates. Keep the new syringe packaging available if one was supplied. Note any differences, including a changed formulation or added ingredient.

You do not need to solve the arithmetic to identify a discrepancy. A useful message to the pharmacy is: "The concentration on this refill is different from my previous vial, but the instruction message looks the same. Please confirm the prescribed amount and the exact marking for this syringe."

Ask for the answer in writing. If the prescribing platform and dispensing pharmacy give different answers, ask them to reconcile the prescription with each other. Do not choose between two conflicting instructions yourself.

Check who actually dispensed the product

The telehealth company collecting payment may be different from the pharmacy dispensing the medicine. Keep both contact details. FDA recommends obtaining a prescription and using a state-licensed pharmacy; it has also identified fraudulent labels naming pharmacies that did not make the product 2.

A printed pharmacy name is therefore a starting point for checking, not a guarantee. If the packaging is unexpected or the pharmacy identity is unclear, contact the pharmacy through independently verified contact information before use.

Our provider checklist explains the questions to ask before payment. For broader product-quality concerns, see compounded GLP-1 safety.

Storage and use dates are separate from concentration

A correct concentration does not answer whether the product has been stored appropriately or remains suitable for use. Read the storage instructions, beyond-use date and any after-first-use directions supplied with that specific product.

Do not assume an unopened beyond-use date means you can keep drawing from a punctured vial until that date. Ask the pharmacy to explain both dates if they are not clear. A plan to use less each week may leave medicine unused; it does not extend the product's instructed use period.

Our compounded tirzepatide refrigeration guide addresses that separate question. The relevant source is the dispensing pharmacy's directions for your product, not a shelf-life claim attached to a different vial online.

If you think you already used the wrong amount

Contact a clinician, pharmacist or poison-control service promptly for assessment. Keep the vial, syringe and instructions available, and note when the medicine was taken. Do not try to compensate with another medicine or alter the next dose without advice.

Severe or persistent vomiting, significant abdominal pain, fainting or inability to keep fluids down warrants urgent medical attention. FDA's dosing-error alert describes serious symptoms after overdoses; the absence of immediate symptoms is not a reliable way to calculate what was taken 1.

When reporting the event, distinguish what you know from what you are unsure about. For example, you may know the syringe marking but not the concentration used. A photo of the label can help a professional reconstruct the event more accurately than a guessed dose.

Make the refill instructions part of the purchase

Before choosing a program, ask how it communicates a concentration change and who answers measuring questions. Ask whether written directions name the prescribed amount, the product concentration and the appropriate syringe. An instructional video for a generic vial does not resolve a mismatch on your own label.

Price comparisons are still useful, but support at the point of dispensing is part of what you are buying. The practical standard is simple: each refill should come with instructions that clearly match that refill.

Frequently asked

Can I use the same syringe marking after a refill?

Only if the current prescription and pharmacy instructions confirm it. A changed concentration can change the amount of drug at the same marking.

Does a larger vial mean a stronger concentration?

Not necessarily. Total drug amount, liquid volume and concentration are different label details. Ask the pharmacist to explain the actual product.

What if the clinic message and pharmacy label disagree?

Do not choose an instruction yourself. Ask the prescriber and dispensing pharmacy to reconcile the prescription before use.

References

  1. U.S. Food and Drug Administration (2024). Dosing errors associated with compounded injectable semaglutide products. FDA. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  2. U.S. Food and Drug Administration (2026). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Continue reading